论文部分内容阅读
目的探讨奥扎格雷钠治疗出血性脑梗死(HI)的临床疗效及安全性。方法将入选的39例HI患者随机分为奥扎格雷钠治疗组20例和对照组19例,治疗组予奥扎格雷80mg加入5%的葡萄糖水静脉滴注,2次/d,其他治疗同对照组。对照组给予中性治疗。两组治疗时间均为14d。各组治疗前后分别进行神经功能障碍评分及疗效分析,监测凝血功能和血小板。结果治疗期间两组患者均无再出血发生;治疗组无再梗死发生,对照组有2例再梗死发生;治疗组治疗后NIHSS均值低于对照组(P<0.05),总显效率和总有效率高于对照组(P<0.05)。结论奥扎格雷治疗HI是安全有效的。
Objective To investigate the clinical efficacy and safety of ozagrel in the treatment of hemorrhagic cerebral infarction (HI). Methods Ninety-one patients with HI were randomly divided into 20 cases of sodium ozagrel treatment group and 19 cases of control group. The treatment group was treated with 80mg of ozagrel 80mg intravenous infusion of glucose water (2% Control group. The control group was given neutral treatment. The two groups were treated for 14 days. Before and after treatment, neurological dysfunction score and curative effect were analyzed respectively, and coagulation function and platelet count were monitored. Results No rebleeding occurred in the two groups during the treatment. No infarction occurred in the treatment group and two cases of reinfarction occurred in the control group. The average NIHSS in the treatment group was lower than that in the control group (P <0.05), and the total effective rate and total Efficiency is higher than the control group (P <0.05). Conclusion Ozagrel treatment of HI is safe and effective.